Identification of Cancer Patients with Lynch Syndrome: Clinically Significant Discordances and Problems in Tissue-Based Mismatch Repair Testing
Open Access
- 1 February 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 5 (2), 320-327
- https://doi.org/10.1158/1940-6207.capr-11-0288
Abstract
Tissue-based microsatellite instability (MSI) analysis and immunohistochemistry for DNA mismatch repair proteins are accepted screening tools to evaluate patients with cancer for Lynch syndrome. These laboratory analyses are thus important tools in cancer prevention. Quality assurance review was conducted to identify test discordances and problems. These results were then analyzed in conjunction with genetic testing outcomes. Six hundred and forty-six consecutive tumors from 2002 to 2010 were examined. MSI-low tumors were excluded so that 591 tumors comprised the final analyses. Discordance was defined as a discrepancy between immunohistochemical and MSI analysis. Problem was defined as indeterminate or questionable immunohistochemical or MSI results. All results and clinical and family histories were centrally reviewed by two pathologists and one genetics counselor. Discordances and problems were identified in 23 of 591 (3.9%) of the tumors. Twelve of 102 MSI-high carcinomas (11.8%) and one of 489 microsatellite stable tumors had discordant immunohistochemistry. Of these 13 tumors, 11 were from patients who had personal and/or family cancer histories concerning for a germline mismatch repair gene mutation. In addition to discordances, 10 tumors with problematic immunohistochemical profiles were identified. Accurate evaluation of MSI was possible in all tumors. In summary, concordance between immunohistochemistry and MSI was high, particularly for tumors that are microsatellite stable. Greater frequency of test discordance was identified in the tumors that were MSI-high. Thus, a major consequence of the use of immunohistochemistry by itself as a screen is the failure to identify colorectal and endometrial cancer patients who likely have Lynch syndrome. Cancer Prev Res; 5(2); 320–7. ©2011 AACR.Keywords
This publication has 31 references indexed in Scilit:
- Detection of genetic alterations in hereditary colorectal cancer screeningMutation research. Reviews in mutation research, 2010
- Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal CancerJournal of Clinical Oncology, 2008
- Immunohistochemistry versus Microsatellite Instability Testing For Screening Colorectal Cancer Patients at Risk For Hereditary Nonpolyposis Colorectal Cancer Syndrome: Part I. The Utility of ImmunohistochemistryThe Journal of Molecular Diagnostics, 2008
- Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancerBritish Journal of Surgery, 2008
- Association of Smoking, CpG Island Methylator Phenotype, and V600E BRAF Mutations in Colon CancerJNCI Journal of the National Cancer Institute, 2006
- Prediction of Germline Mutations and Cancer Risk in the Lynch SyndromeJAMA, 2006
- Is It Time to Abandon Microsatellite Instability As a Pre-Screen for Selecting Families for Mutation Testing for Mismatch Repair Genes?Journal of Clinical Oncology, 2006
- Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinomaLaboratory Investigation, 2006
- Use of Microsatellite Instability and Immunohistochemistry Testing for the Identification of Individuals at Risk for Lynch SyndromeFamilial Cancer, 2005
- Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer)The New England Journal of Medicine, 2005